Vanda Raises Concerns Over FDA Review Timeline for Motion Sickness Therapy Candidate
The regulator has set a target decision date of
Vanda called the
Price: 5.08, Change: +0.10, Percent Change: +2.01
MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.
© 1999-2025 Midnight Trader, Inc. All rights reserved.

Related News
-
Walgreens Boots' Stefano Pessina to almost double stake after Sycamore takeover, FT reports
Reuters - 20 minutes ago
-
NASA astronauts head home on SpaceX capsule after drawn-out space station stay
Reuters - 28 minutes ago
-
Walgreens Boots' Stefano Pessina to almost double stake after Sycamore takeover, FT reports
Reuters - 31 minutes ago
-
Sport-Women's elite sports to generate more than $2.35 billion in 2025, says Deloitte
Reuters - 32 minutes ago
-
Equinix issues its first Singaporean green bonds, raising $375 million
Reuters - 12:21 AM ET 3/18/2025
-
Factbox-Hedge funds, pharma CEOs on list of attendees for China business summit
Reuters - 12:06 AM ET 3/18/2025
-
China begins review of CK Hutchisons' port deal for security concerns, Bloomberg News reports
Reuters - 12:05 AM ET 3/18/2025